NDST1 and neoplasm: The goal was not to examine carcinomatous tumor progression (with anti-tumor cellular immune effects under the CD11cCre+ driven Ndst1 mutation, as in prior work), but to assess whether a mutation relegated only to APCs alters the earliest steps in spontaneous tumor formation in situ.